US5593974A — Localized oligonucleotide therapy

Claim 1

Independent Claim 147 words

A method of inhibiting translation of a target nucleic acid sequence preferentially at a vascular tissue locus in vivo to thereby inhibit restenosis at said locus, the method comprising: directly applying to said vascular tissue locus within the body of a mammal an antisense oligonucleotide, comprising 14 to 38 nucleotide bases, that is complementary to a target nucleic acid sequence expressed in smooth muscle cells and necessary to initiate a target nucleic acid sequence expressed in smooth muscle cells and necessary to initiate or support proliferation thereof, in an amount sufficient to penetrate smooth muscle cells of the tissue at said locus, to hybridize with said target nucleic acid, and to inhibit intracellular translation of said target sequence to thereby inhibit restenosis at said locus, wherein said target nucleic acid is a gene coding for a protein selected from the group consisting of c-myb, NMMHC and PCNA.

Claim 2

Independent Claim 147 words

A method of inhibiting translation of a target nucleic acid sequence preferentially at a vascular tissue locus in vivo to thereby inhibit restenosis at said locus, the method comprising: directly applying to said vascular tissue locus within the body of a mammal an antisense oligonucleotide, comprising 14 to 38 nucleotide bases, that is complementary to a target nucleic acid sequence expressed in smooth muscle cells and necessary to initiate a target nucleic acid sequence expressed in smooth muscle cells and necessary to initiate or support proliferation thereof, in an amount sufficient to penetrate smooth muscle cells of the tissue at said locus, to hybridize with said target nucleic acid, and to inhibit intracellular translation of said target sequence to thereby inhibit restenosis at said locus, wherein said target nucleic acid is a gene coding for a protein selected from the group consisting of c-myb, NMMHC and PCNA.

Claim 3

Dependent Claim 21 words

The method of claim 1 wherein the oligonucleotide is in a physiologically compatible solution and wherein it is applied by injection.

Claim 4

Dependent Claim 20 words

The method of claim 1 wherein the solution is applied to the tissue using an infusion pump, stent, or catheter.

Claim 5

Dependent Claim 21 words

The method of claim 1 wherein the oligonucleotide is treated to render it resistant to degradation or extension by intracellular enzymes.

Claim 6

Dependent Claim 43 words

The method of claim 4 wherein the treatment comprises substituting at least one backbone phosphodiester linkage of the oligonucleotide with a linkage selected from the group consisting of phosphorothioate, methylphosphonate, sulfone, sulfate, ketyl, phosphorodithioate, phosphoramidate, phosphate ester, bridged phosphorothioate and bridged phosphoramidate linkages.

Claim 7

Dependent Claim 20 words

The method of claim 4 wherein the treatment comprises capping a 3'-nucleotide with a structure resistant to addition of nucleotides.

Claim 8

Dependent Claim 31 words

The method of claim 1 wherein the oligonucleotide is delivered to the tissue in a concentration of between approximately 30 and 3000 μg oligonucleotide per square centimeter of tissue surface area.

Claim 9

Dependent Claim 14 words

The method of claim 1 wherein the target nucleic acid sequence comprises an mRNA.

Claim 10

Independent Claim 152 words

A method of inhibiting translation of a target nucleic acid sequence preferentially at a vascular tissue locus in vivo to thereby inhibit restenosis at said locus, the method comprising: directly depositing onto a surface of a vascular tissue locus within the body of a mammal an antisense oligonucleotide of 14 to 38 nucleotide bases that is complementary to a target nucleic acid sequence expressed in smooth muscle cells and necessary to initiate or support proliferation thereof, said oligonucleotide being incorporated within a carrier; and permitting the oligonucleotide to penetrate from said carrier into smooth muscle cells of the tissue at said locus in an amount sufficient to hybridize with said target nucleic acid and to inhibit intracellular translation thereof to inhibit restenosis at said locus, wherein the target nucleic acid comprises an mRNA sequence transcribed from a gene coding for a protein selected from the group consisting of c-myb, NMMHC and PCNA.

Claim 11

Independent Claim 152 words

A method of inhibiting translation of a target nucleic acid sequence preferentially at a vascular tissue locus in vivo to thereby inhibit restenosis at said locus, the method comprising: directly depositing onto a surface of a vascular tissue locus within the body of a mammal an antisense oligonucleotide of 14 to 38 nucleotide bases that is complementary to a target nucleic acid sequence expressed in smooth muscle cells and necessary to initiate or support proliferation thereof, said oligonucleotide being incorporated within a carrier; and permitting the oligonucleotide to penetrate from said carrier into smooth muscle cells of the tissue at said locus in an amount sufficient to hybridize with said target nucleic acid and to inhibit intracellular translation thereof to inhibit restenosis at said locus, wherein the target nucleic acid comprises an mRNA sequence transcribed from a gene coding for a protein selected from the group consisting of c-myb, NMMHC and PCNA.

Claim 12

Dependent Claim 12 words

The method of claim 9 wherein the carrier comprises an implantable matrix.

Claim 13

Dependent Claim 11 words

The method of claim 9 wherein the carrier comprises a hydrogel.

Claim 14

Dependent Claim 21 words

The method of claim 11 wherein the hydrogel comprises a material which is liquid at a temperature below about 37° C.

Claim 15

Dependent Claim 15 words

The method of claim 12 wherein the hydrogel material comprises a polyethylene oxide-polypropylene oxide polymer.

Claim 16

Dependent Claim 30 words

The method of claim 13 wherein the polymer comprises from about 10 to about 80% by weight polyethylene oxide and from about 20 to about 90% by weight polypropylene oxide.

Claim 17

Dependent Claim 22 words

The method of claim 14 wherein the polymer comprises about 70% by weight polyethylene oxide and about 30% by weight polypropylene oxide.

Claim 18

Dependent Claim 15 words

The method of claim 9 wherein the oligonucleotide, incorporated within said carrier, is deposited extravascularly.

Claim 19

Dependent Claim 24 words

The method of claim 9 wherein said oligonucleotide, incorporated within said carrier, is deposited onto or beneath an adventitial surface of the vascular system.

Claim 20

Independent Claim 134 words

A method for inhibiting restenosis at a vascular tissue locus following injury to the locus, the method comprising: directly applying to the locus of a vascular tissue injury in vivo an antisense oligonucleotide, complementary to a target nucleic acid expressed in smooth muscle cells and necessary to initiate or support proliferation thereof, the oligonucleotide being applied at a concentration sufficient to permit the oligonucleotide to penetrate smooth muscle cells at the locus, and to induce selective hybridization between said nucleic acid and said antisense oligonucleotide within the smooth muscle cells for a time sufficient to inhibit restenosis at the locus of the vascular tissue injury, wherein the target nucleic acid comprises a portion of an mRNA encoding a protein selected from the group consisting of a c-myb protein, non-muscle myosin heavy chain and PCNA.

Claim 21

Independent Claim 134 words

A method for inhibiting restenosis at a vascular tissue locus following injury to the locus, the method comprising: directly applying to the locus of a vascular tissue injury in vivo an antisense oligonucleotide, complementary to a target nucleic acid expressed in smooth muscle cells and necessary to initiate or support proliferation thereof, the oligonucleotide being applied at a concentration sufficient to permit the oligonucleotide to penetrate smooth muscle cells at the locus, and to induce selective hybridization between said nucleic acid and said antisense oligonucleotide within the smooth muscle cells for a time sufficient to inhibit restenosis at the locus of the vascular tissue injury, wherein the target nucleic acid comprises a portion of an mRNA encoding a protein selected from the group consisting of a c-myb protein, non-muscle myosin heavy chain and PCNA.

Claim 22

Independent Claim 153 words

A method for inhibiting restenosis at a vascular tissue locus following injury to said locus, the method comprising: directly applying to the locus of a vascular tissue injury in vivo a hydrogel, which is liquid below about 37° C. and gels at body temperature, the hydrogel having incorporated therein an antisense oligonucleotide, complementary to a target nucleic acid expressed in smooth muscle cells and necessary to initiate or support proliferation thereof; and permitting the oligonucleotide present in the hydrogel to diffuse from the hydrogel at a concentration sufficient to permit the oligonucleotide to penetrate smooth muscle cells at the tissue locus and to hybridize with the target nucleic acid for a time sufficient to inhibit restenosis at the locus of the vascular tissue injury, wherein the target nucleic acid comprises a portion of a mRNA encoding a protein selected from the group consisting of a c-myb protein, non-muscle myosin heavy chain and PCNA.

Claim 23

Independent Claim 153 words

A method for inhibiting restenosis at a vascular tissue locus following injury to said locus, the method comprising: directly applying to the locus of a vascular tissue injury in vivo a hydrogel, which is liquid below about 37° C. and gels at body temperature, the hydrogel having incorporated therein an antisense oligonucleotide, complementary to a target nucleic acid expressed in smooth muscle cells and necessary to initiate or support proliferation thereof; and permitting the oligonucleotide present in the hydrogel to diffuse from the hydrogel at a concentration sufficient to permit the oligonucleotide to penetrate smooth muscle cells at the tissue locus and to hybridize with the target nucleic acid for a time sufficient to inhibit restenosis at the locus of the vascular tissue injury, wherein the target nucleic acid comprises a portion of a mRNA encoding a protein selected from the group consisting of a c-myb protein, non-muscle myosin heavy chain and PCNA.

Claim 24

Dependent Claim 17 words

The method of claim 19 wherein said hydrogel comprises a polymer of ethylene oxide-propylene oxide repeating units.

Annuity Stage	Window Opens	Payment Deadline	Surcharge Period Until	Estimated Fee	Status
3.5 Years (Year 4)	2000-01-14	2000-07-15	2001-01-14	$2000.00	Window Closed / Lapsed
7.5 Years (Year 8)	2004-01-14	2004-07-15	2005-01-14	$3760.00	Window Closed / Lapsed
11.5 Years (Year 12)	2008-01-14	2008-07-15	2009-01-14	$7700.00	Window Closed / Lapsed

Localized oligonucleotide therapy

Abstract

Inventors

Bibliographic Details

Claims Analysis

References Cited (Backward Citations)

USPTO Annuity & Maintenance Windows

Assigned Categories & Tags

Assign Category Tag